Royal College of Surgeons of Edinburgh launches MRCS ophthalmology exam, Fellowship to follow

Article

A new MRCS ophthalmology examination will be offered to ICO College Members beginning in 2022.

Royal College of Surgeons of Edinburgh launches MRCS ophthalmology exam, Fellowship to follow

The Royal College of Surgeons of Edinburgh (RCSEd), a leading surgical college, announced the launch of its own Membership of the Royal College of Surgeons (MRCS) ophthalmology examination.

This new examination will be available in early 2022, and a Fellowship examination will follow later in the year.

Professor Michael Griffin OBE, President of the RCSEd

Professor Michael Griffin OBE

“We would like to thank the ICO for the very positive relationship we have enjoyed over the last few years and wish them the best in their pursuit of improving standards in global Ophthalmology care,” said Professor Michael Griffin OBE, President of the RCSEd. “We are delighted to now have the opportunity to launch our very own MRCS Ophthalmology and look forward to adding a Fellowship examination next year, ensuring those in the profession will have a continued route into College membership.”

RCSEd was first incorporated as the Barber Surgeons of Edinburgh in 1505, and it has since grown to nearly 29,000 members from 100 countries worldwide, with 15,000 in the UK. As one of the oldest surgical corporations in the world, the College promotes the high standards in surgical and dental practice. The College is also home of the UK’s only Faculty of Surgical Trainers, which is open to anyone with interest in surgical training, regardless of College affiliation.

All ICO College Members—including the April intake of this year—are eligible for the full benefits and services the College offers.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.